Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/21036735http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/21036735http://www.w3.org/2000/01/rdf-schema#comment"

Aim

The aim of this study was to explore possible differences in the mRNA expression levels of CRIM1, SMAD5, BMP4 and BMP7 in sensitive (S) and multidrug-resistant (R0.5) myeloid leukemia HL60 cells.

Materials and methods

HL60S and HL60R0.5 cells were exposed to daunorubicin (DNR) or cytarabine (Ara-C).

Results

Baseline levels of CRIM1 were found to be 15-fold higher in HL60R0.5 than in HL60S. Sixteen hours of exposure to DNR resulted in a 5.6-fold increase in CRIM1 levels in HL60S. Exposure to either DNR or Ara-C resulted in modest increases in CRIM1 levels in HL60R0.5. Similarly, baseline levels of SMAD5 and BMP4 were higher in HL60R0.5 than in HL60S cells. Analysis of the drug SMAD5-resistance marker permeability-glycoprotein (Pgp) revealed that CRIM1 and Pgp exhibit a covariance pattern of expression.

Conclusion

This study demonstrated that CRIM1 is expressed at high levels in resistant leukemia cells, indicating that CRIM1 may play a role in drug-resistance."xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/author"Strid H."xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/author"Tidefelt U."xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/author"Uggla B."xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/author"Prenkert M."xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/date"2010"xsd:gYear
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/name"Anticancer Res"xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/pages"4157-4161"xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/title"CRIM1 is expressed at higher levels in drug-resistant than in drug-sensitive myeloid leukemia HL60 cells."xsd:string
http://purl.uniprot.org/citations/21036735http://purl.uniprot.org/core/volume"30"xsd:string
http://purl.uniprot.org/citations/21036735http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/21036735
http://purl.uniprot.org/citations/21036735http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/21036735
http://purl.uniprot.org/uniprot/#_B4DUW0-mappedCitation-21036735http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/#_Q53TH9-mappedCitation-21036735http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/#_Q53TR0-mappedCitation-21036735http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/#_Q4ZG85-mappedCitation-21036735http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/#_Q9NZV1-mappedCitation-21036735http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/Q4ZG85http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/Q9NZV1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/Q53TR0http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/B4DUW0http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/21036735
http://purl.uniprot.org/uniprot/Q53TH9http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/21036735